Trial Profile
A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Nivocasan (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 02 Apr 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 06 Nov 2012 Planned number of patients changed from 240 to 330 as reported by European Clinical Trials Database record.
- 16 Jul 2012 This trial is recruiting in Germany.